Abstract
Since the first description of Alzheimer’s disease (AD) at the beginning of the century until relatively recently, it was customary to define Alzheimer’s disease as occurring in the presenium. The same neuropathological changes occurring in brains over the age of 65 were called “senile dementia.” Because there have been no clinical or pathological features to separate the two groups, this somewhat arbitrary distinction has been abandoned. Although AD is currently considered to be a heterogeneous disease, the most consistent risk factor to be implicated other than advancing age is the presence of a positive family history. This potential genetic vulnerability to AD has been recognized for some time. Some of the earliest evidence suggestive of a genetic contribution to AD came from Kallmann’s 1956 study (1) demonstrating a higher concordance rate in monozygotic twins for “parenchymatous senile dementia” compared with dizygotic twins and siblings. This monozygotic excess has been confirmed in studies applying more rigorous diagnostic criteria although there may be widely disparate ages of onset between twins (2). The most convincing evidence for a genetic contribution to AD has come form the study of pedigrees in which the pattern of disease segregation can be clearly defined. Thus, the abandonment of the early and late-onset dichotomy has occurred at a time when, at the genetic level, important differences have been identified through the discovery of specific gene defects in early onset cases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kallmann, F. J. (1956) Genetic aspects of mental disorders in late life, in Mental Disorders In Late Life (Kaplan, O. J., ed.), Stanford University Press, Palo Alto, CA.
Brietner, J. C. S., Gatz, M., and Gergem, A. C. M. (1993) Use of twin cohorts for research in Alzheimer’s disease. Neurology 43, 261–267.
Heston, L. L., Mastri, A. R., Anderson, E., and White, J. (1981) Dementia of the Alzheimer type. Clinical genetics, natural history and associated conditions. Arch. Gen. Psych. 112, 227–239.
Thal, L. J., Grundman, M., and Klauber, M. R. (1988) Dementia: characteristics of a referral population and factors associated with progression. Neurology 38, 1083–1090.
Hofman, A., Schulte, W., Tanja, T. A., et al. (1989) History of dementia and Parkinson′s disease in first degree relatives of patients with Alzheimer’s disease. Neurology 39, 1589–1592.
Hoininen, H. and Heinonen, O. P. (1982) Clinical and etiological aspests of senile dementia. Eur. Neurol. 21, 401–410.
Heyman, A., Wilkinson, W. E., Stafford, J. A., Helms, M. J., Sigmon, A. H., and Weinberg, T. (1984) Alzheimer’s disease: a study of epidemiological aspects. Ann. Neurol. 15, 335–341.
Huff, J., Auerbach, J., Chackravarti, A., and Boller, F. (1988) Risk of dementia in relatives of patients with Alzheimer’s disease. Neurology 38, 786–790.
Breitner, J. C., Silverman, J. M., Mohs, R. C., and Davis, K. L. (1988) Familial aggregation in Alzheimer’s disease: comparison of risk among relatives of early-and late-onset cases, and among male and female relatives in successive generations. Neurology 38, 207–212.
van Duijn, C. M., Clayton, D., Chandra, C. M., Fratiglioni, L, Graves, A. B, Heyman, A., et al. (1991) Familial aggregation of Alzheimer’s disease and related disorders: a collaborative re-analysis of case control. studies. Int. J. Epidemiol. 20 (suppl.2), S13–S20.
Yatham, L. N., McHale, P. A., and Kinsella, A. (1988) Down′s syndrome and its association with Alzheimer’s disease. Acta. Psychiatr. Scand. 77, 38–41.
H. Broe, G. A., Henderson, A. S., Creasey, H., McCusker, E., Korten, A. E., Jorm, A. F., et al. (1990) A case control. study of Alzheimer’s disease in Australia. Neurology 40, 1698–1707.
Zubenko, G. S., Huff, H. J., Beyer, J., Auerbach, J., and Teply, I. (1988) Familial risk of dementia associated with a biologic subtype of Alzheimer’s disease. Arch. Gen. Psych. 45, 889–893.
Berr, C., Borghi, E., Rethore, M. O., Lejeune, J., and Alperovitch, A. (1989) Absence of familial association between dementia of the Alzheimer type and Down′s syndrome. Am. J. Med. Genet. 33, 545–550.
Breitner, J. C. S. and Folstein, M. F. (1984) Familial Alzheimer dementia: aprevalent disorder with specific clinical features. Psychol. Med. 14, 63–80.
Farrer, L. A., Meyers, R. H., Cupples, L. A., et al. (1990) Transmission and age at onset patterns in familial Alzheimer’s disease: evidence of heterogeneity. Neurology 40, 395–03.
Pericak-Vance, M. A., Bass, M. P., Yamaoka, L. H., Gaskell P. C., Scott, W. K., Terwedow, H. A., et al. (1997) Complete genomic screen in late onset familial Alzheimer’s disease. Evidence for a new locus on chromosome 12. JAMA 278, 1237–1241.
Rogaeva, E., Premkumar, S., Song, Y. Q., Sorbi, S., Brindle, N., Paterson, A., et al. (1998) Evidence for an Alzheimer disease susceptibility locus on chromosome 12 and for further locus heterogeneity. JAMA 280, 614–618.
Wu, W. S., Holmans, P., Wavrant-Devrieze, F., Shears, S., Kehoe, P., Crook, R., et al. (1998) Genetic studies on chromosome 12 in late-onset Alzheimer disease. JAMA 280, 619–622.
Pericak-Vance, M. A., Bass, M. P., Yamaoka, L. H., Gaskell P. C., Scott, W. K., Terwedow, H. A., et al. (1991) Linkage studies in familial Alzheimer’s disease-evidence for chromosome 19 linkage. Am. J. Hum. Genet. 48, 1034–1050.
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., and Roses, A. D. (1993) Apolipoprotein E-high-avidity binding to beta-amyloid and increased frequency of type-4 allele in late-onset familial Alzheimer-disease. Proc. Natl. Acad. Sci. USA 90, 1977–1981.
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., et al. (1993) Association of Apolipoprotein E allele ε4 with the late onset familial and sporadic Alzheimer’s disease. Neurology 43, 1467–1472.
Corder, E. H., Saunders, A. M., Strittmatter, W. J., et al. (1993) Gene dosage of apolipoprotein E type 4 allele and the risk for Alzheimer’s disease in late onset families. Science 261, 921–923.
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., et al. (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer’s disease. Nature Genet. 7, 180–184.
Evans, D. A., Beckett, L. A., Field, T. S., Feng, L., Albert, M. S., Bennett, D. A., et al. (1997) Apolipoprotein E ε4 and incidence of Alzheimer’s disease in a community population of older persons. JAMA 277, 822–824.
Osuntokun, B. O., Sahota, A., Ogunniyi, A. O., Gureje, O., Baiyewu, O., Adeyinka, A., et al. (1995) Lack of association between Apolipoprotein Eε4 and Alzheimer’s disease in elderly Nigerians. Ann. Neurol. 38, 463–465.
Hendrie, H. C., Hall, K. S., Hui, S., Unverzagt, F. W., Yu, C. E., Lahiri, D. K., et al. (1995) Apolipoprotein E genotypes and Alzheimer’s disease in a community study of elderly African Americans. Ann. Neurol. 37, 118–120.
Tang, M. X., Stern, Y., Marder, K., Bell, K., Gurland, B., Lantigua, R., et al. (1998) The ApoE-ε4 allele and the risk of Alzheimer’s disease among African-Americans, whites and Hispanics. JAMA 279, 751–755.
Farrer, L. A., Cupples, L. A., Myers, R. H., van Duijn, C. M., Mayeux, R., Haines, J. L., et al. (1998) Effects of age and ethnicity on the link between Apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA 278, 1349–1356.
Strittmatter, W. J., Saunders, A. M., Goedert, M., Weisgraber, K. H., Dong, L. M., Jakes, R., et al. (1995) Purification of apolipoprotein E attenuates isoform specific binding to β-amyloid. J. Biol. Chem. 270, 9039–9042.
LaDu, M. J., Falduto, M. T., Manelli, A. M., Reardon, C. A., Getz, G. S., Frail, D. E. (1994) Isoform specific binding of apolipoprotein E to b amyloid. J. Biol. Chem. 269, 23,403–23,406.
Zhou, Z., Smith, J. D., Greengard, P. and Gandy, S. (1996) Alzheimer amyloid β peptide forms denaturant resistant complex with type E3 but not type E4 isoform of apolipoprotein E. Mol. Med. 2, 175–180.
Strittmatter, W. J., Saunders, A. M., Goedert, M., Weisgraber, K. H., Dong, L. M., Jakes, R., et al. (1994) Isoform specific interactions of Apolipoprotein E with microtubule associated protein tau: implications for Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 91, 11183–11186.
Huang, D. Y., Goedert, M., Jakes, R., Weisgraber, K. H., Garner, C. C., Saunders, A. M., et al. (1994) Isoform-specific interactions of Apolipoprotein-E with the microtu-bule-associated protein MAP2c-implications for Alzheimer’s-disease. Neurosci. Lett. 182(1), 55–58.
Nathan, B. P., Bellosta, S., Sanan, D. A., Weisgraber, K. H., Mahley, R. W., and Pitas, R. E. (1994) Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264, 850–852.
Lehtovirta, M., Soininen, H., Laakso, M. P., Partanen, K., Helisalmi, S., Mannermaa, A., et al. (1996) SPECT and MRI analysis in Alzheimer’s disease: relation to apolipoprotein E epsilon-4 allele. J. Neurol. Neurosurg. Psychiat. 60, 644–649.
Gomez-Isla, T., West, H. L., Rebeck, G. W., Harr, S. D., Growdon, J. H., Locascio, J. J., et al. (1996) Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer’s disease. Ann. Neurol. 39, 62–70.
Benjamin, R., Leake, A., Edwardson, J. A., McKeith, J. G., Ince, P. G., Perry, R. H., and Morris, C. M. (1994) Apolipoprotein E genes in Lewy body and Parkinson′s disease. Lancet 343, 1565.
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K. W., Bandy, D., Minoshima, S., et al. (1996) Preclinical evidence of Alzheimer’s disease in persons homozygous of epsilon 4 allele for apolipoprotein E. N. Engl. J. Med. 334, 752–758.
Jervis, G. A. (1948) Early senile dementia in Mongoloid idiocy. Am. J. Psychiatry 105, 102–106.
Goate, A., Chartier-Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani, L., et al. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349, 704–706.
Chartier-Harlin, M. C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., et al. (1991) Early onset Alzheimer’s disease caused by mutation at codon 717 of the β-amyloid precursor protein gene. Nature 353, 844–846.
Murrel, J., Farlow, M., Ghetti, B., and Benon, M. D. (1991) A mutation in the amyloid precursor protein associated with hereditary Alzheimer’s disease. Science 254, 97–99.
Kennedy, A. M, Newman, S., McCaddon, A., Ball, J., Roques, P., Mullan, M., et al. (1993) Familial Alzheimer’s disease: a pedigree with a missense mutation in the amyloid precursor protein (amyloid precursor protein 717 valine-glycine). Brain 116, 309–324.
Farlow, M., Murrell, J., Ghetti, B., Unverzagt, F., Zeldenrust, S., and Benson, M. (1994) Clinical characteristics in a kindred with early onset Alzheimer’s disease and their linkage to a G-T change at position 2149 of the amyloid precursor protein gene. Neurology 44, 105–111.
Mullen, M., Crawford, F., Axelman, K., et al. (1992) A new mutation in APP demonstrates that the pathogenic mutations for probable Alzheimer’s disease frame the β-amyloid sequence. Nature Genet. 1, 345–347.
Levy, E., Carman, M. D., Fernandez-Madrid, I. J., Levy, E., Carman, M. D., Fernandez-Madrid, I. J., et al. (1990) Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral haemorrhage, Dutch Type. Science 248, 1124–1126.
Tanzi, R. E., Vaula, G., Romano, D. M., Mortilla, M., Huang, T. L., Tupler, R. G., et al. (1992) Assessment of amyloid beta protein gene mutations in a large set of familial and sporadic Alzheimer’s disease cases. Am. J. Hum. Genet. 51, 273–282.
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A., Seubert, P., et al. (1992) Mutation of the β-amyloid precursor protein in familial Alzheimer’s disease increases β-protein production. Nature 360, 672–674.
Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., et al. (1995) Alzheimer type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373, 523–527.
Schellenberg, G. D., Bird, T. D., Wijsman, E. M., Orr, H. T., Anderson, L., Nemens, E., et al. (1992) Genetic linkage evidence for a Familial Alzheimer’s disease locus on chr 14. Science 258, 668–671.
St George-Hyslop, P., Haines, J., Rogaev, E., Mortilla, M., Vaula, G., Pericak-Vance, M., et al. (1992) Genetic evidence for a novel familial Alzheimer’s disease gene on chromosome 14. Nature Genet. 2, 330–334.
5Van Broeckhoven, C., Backhovens, H., Cruts, M., DeWinter, G., Bruyland, M., Cras, P., and Martin, J. J. (1992) Mapping of a gene predisposing to early-onset Alzheimer’s disease to chromosome 14q24.3. Nature Genet. 2, 335–339.
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., et al. (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 375, 754–760.
Perez-Tur, J., Froelich, S., Prihar, G., Crook, R., Baker, M., Duff, K., et al. (1996) A mutation in the splice acceptor site in the presenilin-1 gene. Neuroreport 7, 297–301.
Tysoe, C., Whittaker, J., Xuereb, J., Cairns, N. J., Cruts, M., Van Broeckhoven, C., et al. (1998) Apresenilin-1 truncating mutation is present in two cases with autopsy confirmed early-onset Alzheimer’s disease. Am. J. Hum. Genet. 62, 70–76.
Levy-Lehad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., et al. (1995) A familial Alzheimer’s disease locus on chromosome 1. Science 269, 973–977.
Rogaev, E., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., et al. (1995) Familial Alzheimer’s disease in kindred with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature 376, 775–778.
Levy-Lehad, E., Wasco, W., and Poorkaj, P. (1995) Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 269, 973–977.
Sherrington, R., Froelich, S., Sorbi, S., Campion, D., Chi, H., Rogaeva, E. A., et al. (1996) Alzheimer’s disease associated with mutations in PS-2 is rare and variably penetrant. Hum. Molec Genet. 5, 985–988.
Clark, R. F., Hutton, M., Fuldner, R. A., Froelich, S., Karran, E., Talbot, C., et al. (1995) The structure of the Presenilin 1(S 182) gene and identification of six novel mutations in early onset AD families. Nature Genet. 11, 219–222.
Anwar, R., Moynihan, T. P., Ardley, H., Brindle, N., Coletta, P. L., Cairns, N., et al. (1996) Molecular analysis of the Presenilin-1 (S-182) gene in sporadic cases of Alzheimer’s disease: identification and characterisation of unusual splice variants. J. Neurochem. 66, 1774–1777.
De Strooper, B., Beullens, M., Contreras, B., Levesque, L., Craessaerts, K., Cordell, B., et al. (1997) Phosphorylation, subcellular localisation and membrane orientation of the Alzheimer’s disease associated presenilins. J. Biol. Chem. 272, 3590–3598.
Doan, A., Thinakara, G., Borchelt, D. R., Slunt, H. H., Ratovitsky, T., Podlisny, M., et al. (1996) Protein topology of presenilin-1. Neuron 17, 1023–1030.
Dewji, N. and Singer, S. J. (1997) The seven-transmembrane spanning topology of the Alzheimer’s disease related presenilin protein in the plasma membrane of cultured cells. Proc. Natl. Acad. Sci. USA 94, 14,025–14,030.
Levitan, D. and Greenwald, I. (1995) Facilitation of lin-12 mediated signalling by sel-12, a Caenorrhabditis elegans S182 Alzheimer’s disease gene. Nature 377, 351–354.
Levitan, D., Doyle, T. G., Brousseau, D., Lee, M. K., Thinakaran, G., Slunt, H. H., et al. (1996) Assessment of normal and mutant presenilin function in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA 93,14,940–14,944.
Shen, J., Bronson, R. T., Chen, D. F., Xia, W., Selkoe, O., J., and Tonegawa, S. (1997) Skeketal and CNS deficits in presenilin-1 deficient mice. Cell 89, 629–639.
Hartmann, H., Busciglio, J., Baumann, K. H., Staufenbiel, M., and Yankner, B. A. (1997) Developmental regulation of presenilin-1 processing in the brain suggests a role in neuronal differentiation. J. Biol. Chem. 272, 14505–14508.
Capell, A., Saffrich, R., Olivo, J. C., Meyn, L., Walter, J., Grunberg, J., et al. (1997) Cellular expression and proteolytic processing of presenilin proteins is develop-mentally regulated during neuronal differentiation. J. Neurochem. 69, 2432–2440.
Berezovska, O., Xia, M. Q., Page, K., Wasco, W., Tanzi, R. E., and Hyman, B. T. (1997) Developmental regulation of presenilin mRNA expression parallels notch expression. J. Neuropath. Exp. Neurol. 56, 40–44.
Kim, T. W., Pettingell, W. H., Jung, Y. K., Kovacs, D. M., and Tanzi, R. E. (1997) Alternative cleavage of Alzheimer’s associated presenilins during apoptosis by caspase-3 family proteases. Science 277, 373–376.
Brockhaus, M., Grunberg, J., Rohrig, S., Loetscher, H., Wittenburg, N., Baumeister, R., et al. (1998) Caspase-mediated cleavage is not required for the activity of presenilins in amyloidogenesis and NOTCH signaling. Neuroreport 9, 1481–1486.
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., et al. (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat. Med. 2, 864–870.
Borchelt, D. R., Thinakaran, M. G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., et al. (1996) Familial Alzheimer’s disease linked presenilin-1 variants elevate A beta 1 2/1-40 ratio in vitro and in vivo. Neuron 17, 1005–1013.
Citron, M., Westaway, D., Xia, W. M., Carlson, G., Diehl, T., Levesque, G., et al. (1997) Mutant presenilins of Alzheimer’s disease increase production of 42 residue amyloid beta protein on both transfected cells and transgenic mice. Nature Med. 3, 67–72.
Holcomb, L., Gordon, M.N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., et al. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Med. 4, 97–100.
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., et al. (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387–390.
Yu, G., Chen, E S., Levesque, G., Nishimura, M., Zhang, D. M., Levesque, L., et al. (1998) The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains beta-catenin. J. Biol. Chem. 273, 16,470–16,475.
Schellenberg, G. D., Deeb, S. S., Boehnke, M., Bryant, E. M., Martin, G. M., Lampe, T. H., and Bird, T. D. (1987) Association of apolipoprotein CII with familial dementia of the Alzheimer type. J. Neurogenet. 4, 97–108.
Schellenberg, G. D., Boehnke, M., Wijsman, E. M., Moore, D. K., Martin, G. M., and Bird, T. D. (1992) Genetic association and linkage analysis of the Ap°CII locus and familial Alzheimer’s disease. Ann. Neurol. 31, 223–227.
Bullido, M. J., Artiga, M. J., Recuero, M., Sastre, I., Garcia, M. A., Aldudo, J., et al. (1998). A polymorphism in the regulator region of Apolipoprotein E associated with risk for Alzheimer’s dementia. Nature Genet. 18, 69–71.
Song, Y.-Q., Rogaeva, E., Premkumar, S., Brindle, N., Kawarai, T., Orlacchio, A., et al. (1998) Absence of association between Alzheimer disease and the-491 regulatory region polymorphism of APOE. Neurosci. Letts. 250, 189–192.
Okuizumi, K., Onodera, O., Namba, Y., Ikeda, K., Yamamoto, T., Seki, K., et al. (1996) Genetic association of very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer’s disease. Nature Genet. 11, 207–209.
Fallin, D., Gauntlett, A. C., Scibelli, P., Cai, X. G., Duara, R., Gold M., et al. (1997) No association between the very-low density lipoprotein receptor gene and late-onset Alzheimer’s disease, nor interaction with apolipoprotein E gene in population based and clinic samples. Genet. Epidem. 14, 299–205.
Chen, L., Baum, L., Ng, H. K., Chan, Y. S., Mak, Y. T., Woo, J., et al. (1998) No association detected between the very low density lipoprotein receptor (VLDL-R) and late onset Alzheimer’s disease in Hong Kong Chinese. Neurosci. Lett. 241, 33–36.
Okuizumi, K., Onodera, O., Seki, T., Tanaka, H., Namba, Y., Ikeda, K., et al. (1997) Lack of association of the very-low density lipoprotein receptor gene polymorphism with Caucasian Alzheimer’s disease. Am. J. Hum. Genet. 61, 1686.
Lendon, C. L., Talbot, C. J., Craddock, N. J., Han, S. W., Wragg, M., Morris, J. C., and Goate, A. M. (1997) Genetic association studies between dementia of the Alzheimer’s type and three receptors for apolipoprotein E in a Caucasian population. Neurosci. Lett. 222, 187–190.
Wavrant DeVrieze, F., Perez-Tur, J., Lambert, J. C., Frigard, B., Pasquier, F., Delacourte, A., et al. (1997) Association between the low density lipoprotein receptor-related protein (LRP) and Alzheimer’s disease. Neurosci. Lett. 227, 68–70.
Kang, D. E., Saitoh, T., Chen, X., Xia, Y., Masliah, E., Hansen, L. A., et al. (1997) Genetic association of the low density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor with late onset Alzheimer’s disease. Neurology 49, 56–61.
Fallin, D., Kundz, A., Town, T., Fallin, D., Kundtz, A., Town, T., Gauntlett, A. C., Duara, R., Barker, W., Crawford, F., and Mullan, M. (1997) No association between the low density lipoprotein receptor related protein and late onset Alzheimer’s disease. Am. J. Hum. Genet. 61, 1143.
Wragg, M., Hutton, M., Talbot, C., Busfield, F., Han, S. W., Lendon, C., Clark, R. F., et al. (1996) Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer’s disease. Lancet 347, 509–512.
Kehoe, P., Williams, J., Lovestone, S., Wilcock, G., and Owen, M. J. (1996) Presenilin polymorphism and Alzheimer’s disease. Lancet 347, 1185.
Perez-Tur, J., Wavrant-De Vrieze, F., Lambert, J. C., et al. (1996) Presenilin polymorphism and Alzheimer’s disease. Lancet 347, 1560–1561.
Scott, W. K., Growdon, J. H., Roses, A. D., Haines, J. L., Pericak-Vance, M. A. (1996) Presenilin polymorphism and Alzheimer’s disease. Lancet 347, 1186–1187.
Scott, W. K., Yamaoka, L. H., Locke, P.A., Rosi, B. L., Gaskell, P. C., Saunders, A. M., et al. (1997) No association or linkage between an intronic polymorphism of presenilin-1 and sporadic or late onset familial Alzheimer’s disease. Genet. Epidemiol. 14, 307–315.
Cai, X. G., Stanton, J., Fallin. D., Hoyne, J., Duara, R., Gold, M., et al. (1997) No association between the intronic presenilin-1 polymorphism and Alzheimer’s disease in clinic based and population based samples. Am. J. Hum. Genet. 74, 202–203.
Kamboh, M. I., Sanghera, D. K., Ferrell, R. E., and DeKosky, S. T. (1995) APOE 4 associated Alzheimer’s disease risk is modified by alpha-1-antichymotrypsin polymorphism. Nature Genet. 10, 486–488.
Muramatsu, T., Matsushita, S., Arai, H., Sasaki, H., and Higuchi, S. (1996) Alpha-1-antichymotrypsin gene polymorphism and risk for Alzheimer’s disease. J. Neurol. Trans. 103, 1205–1210.
Yoshiiwa, A., Kamino, K., Yamamoto, H., Kobayashi, T., Imagawa, M., Nonomura, Y., et al. (1997) Alpha-1-antichymotrypsin as a risk modifier for late onset Alzheimer’s disease in Japanese apolipoprotein ε4 allele carriers. Ann. Neurol. 42, 115–117.
Wischik, C., Harrington, C., and Kalsheker, N. A. (1997) Microsatellite polymorphism of the alph-1-antichymotrypsin gene locus associated with sporadic Alzheimer’s disease. Hum. Genet. 99, 27–31.
Muller, U., Bodeker, R. H., Gerundt, I., and Kurz, A. (1996) Lack of association between alpha-1-antichymotrypsin polymorphism, Alzheimer’s disease and allele ε4 of apolipoprotein E. Neurology 47, 1575–1577.
Haines, J. L., Pritchard, M. L., Saunders, A. M., Schildkraut, J. M., Growdon, J. H., Gaskell, P. C., et al. (1996) No association between alpha-1-antichymotrypsin and familial Alzheimer’s disease. Ann. NY Ac ad. Sci. 802, 35–41.
Murphy G. M., Sullivan, E. V., Gallagher Thompson, D., Thompson, L. W., van Duijn, C. M., Forno, L. S., et al. (1997) No association between the alpha-1-antichymotrypsin A allele and Alzheimer’s disease. Neurology 48, 1313–1316.
Fallin, D., Reading, S., Schinka, et al. (1997) No interaction between the ApoE and the alpha-1-antichymotrysin genes on risk for Alzheimer’s disease. Am. J. Med. Genet. 74, 192–194.
Lehmann, D. J., Johnson, C., and Smith, A. D. (1997) Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late onset confirmed Alzheimer’s Disease. Hum. Mol. Genet. 6, 1933–1936.
Sandbrink, R., Gasperina, A., Zarfass, R., Weber, B., Masters, C. L., Beyreuther, K., and Heuser, I. (1998) Butyrylcholinesterase K variant (BCHE-K): association with late-onset Alzheimer’s disease. Neurobiol. Aging 19, S69.
Brindle, N., Song, Y., Rogaeva, E., Premkumar, S., Levesque, G., Yu, G., et al. (1998) Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer’s disease and aging. Hum. Mol. Genet. 7, 933–935.
Singleton, A. B., Smith, G., Gibson, A. M., Woodward, R., Perry, R., Ince, P., et al. (1998) No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer’s disease. Hum. Mol. Genet. 7, 937–939.
Montoya, S. E., Aston, C. E., DeKosky, S. T., Kamboh, M. I., Lazo, J. S., and Ferrell, R. E. (1998) Bleomycin hydroloase is associated with risk of sporadic Alzheimer’s disease. Nature Genet. 18, 211–212.
Premkumar, S., Song, Y., Pericak-Vance, M., Haines, J. L., Rogaeva, E., Scott, W. K., et al. (1998) Analysis of the association between bleomycin hydrolase and Alzheimer’s disease in Caucasians. Neurobiol. Aging 19, S68.
Blacker, D., Wilcox, M. A., Laird, N. M., Rodes, L., Horvath, S. M., Go, P. C. P., et al. (1998) Alpha-2-macroglobulin is genetically asociated with Alzheimer’s disease. Nature Genet. 19, 357–360.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Brindle, N., George-Hyslop, P.S. (2000). The Genetics of Alzheimer's Disease. In: Hooper, N.M. (eds) Alzheimer's Disease. Methods in Molecular Medicine™, vol 32. Humana Press. https://doi.org/10.1385/1-59259-195-7:23
Download citation
DOI: https://doi.org/10.1385/1-59259-195-7:23
Publisher Name: Humana Press
Print ISBN: 978-0-89603-737-3
Online ISBN: 978-1-59259-195-4
eBook Packages: Springer Protocols